Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/04/065493
CTRI/2024/04/065493
Recruiting
Phase 1

A Phase I/IIa, Open Label, Dose-Escalation, First in Human (FIH) study evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in patients with relapsed advanced malignancies - NI

Aurigene Oncology Limited0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: C920- Acute myeloblastic leukemia

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Health Condition 1: C920- Acute myeloblastic leukemia
Sponsor
Aurigene Oncology Limited
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Aurigene Oncology Limited

Eligibility Criteria

Inclusion Criteria

  • •Diagnosis of Acute myeloid leukemia (AML) according to the World Health Organization criteria. OR
  • •Myelodysplastic syndrome (MDS) according to the WHO classification.
  • •Provide signed and dated informed consent and agree to comply with all study related activities.
  • •ECOG status of 0 or 1\.

Exclusion Criteria

  • •Acute promyelocytic leukemia.
  • •Patients eligible for intensive chemotherapy for AML.
  • •Pregnant or lactating women.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)Pediatric Solid tumors and primary central nervous system (CNS) tumorsMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
CTIS2023-505088-35-00F. Hoffmann-La Roche AG93
Active, not recruiting
Not Applicable
A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophyDuchenne Muscular Dystrophy
EUCTR2009-013762-63-NLProsensa Therapeutics B.V18
Active, not recruiting
Phase 1
A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophyDuchenne Muscular Dystrophy
EUCTR2009-013762-63-BEProsensa Therapeutics B.V24
Active, not recruiting
Not Applicable
A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophy - ND
EUCTR2009-013762-63-ITPROSENSA THERAPEUTICS BV18
Active, not recruiting
Not Applicable
A study to assess the effect and safety of multiple subcutaneous and intravenous doses of PRO044 in patients with Duchenne DiseaseDuchenne Muscular DystrophyMedDRA version: 14.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2009-013762-63-SEProsensa Therapeutics B.V24